CLEVELAND - For men age 50 and over, the PSA, or prostate-specific antigen blood test, has been the recommended screening test for prostate cancer for years. It's also a test that some experts have ...

Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, has appointed Rich Ramko to its Board of Directors. Ramko's extensive financial leadership across the biotech, ...

Seasoned life sciences financial advisor brings over 30 years of industry expertise to Cleveland Diagnostics at pivotal time of growth Cleveland Diagnostics, Inc., a pioneering, commercial-stage ...

Regulatory milestone positions Cleveland Diagnostics for faster transition from FDA approval to commercial expansion of its novel prostate cancer test Cleveland Diagnostics, Inc., a commercial-stage ...

CLEVELAND, May 12, 2026--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage precision oncology company, recently received ISO 13485:2016 certification, the globally recognized standard ...

Faced with a dwindling population, shifts in manufacturing and a slow job market, our region’s leaders came together in the early 2000s to reinvigorate a floundering economy. JumpStart was born from ...

The Food and Drug Administration recently approved the IsoPSA blood test, which was developed by Cleveland Diagnostics, a Cleveland Clinic Innovations portfolio company, which looks for specific ...

Cleveland Diagnostics said this week that Michael Iskra is joining the company as its new CEO to accelerate commercial expansion of the IsoPSA prostate cancer assay. The company obtained Food and Drug ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Ellen Lee Ellen Lee is a writer focused on parenting and health gear. She has ...

FDA Approves New IsoPSA Blood Test to Pinpoint Aggressive Prostate Cancer The FDA has approved a novel blood test called IsoPSA that helps pinpoint aggressive prostate cancer in men over 50 with ...